INT266742

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 0.36
Pain Relevance 1.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) Golgi apparatus (GOPC) plasma membrane (GOPC)
DNA binding (ACR) protein complex (ACR) cytoplasm (GOPC)
GOPC (Homo sapiens)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 321 100.00 Very High Very High Very High
diclofenac 3 64.24 Quite High
rheumatoid arthritis 96 61.56 Quite High
Pain 3 46.08 Quite Low
Inflammation 9 5.00 Very Low Very Low Very Low
Arthritis 6 5.00 Very Low Very Low Very Low
antagonist 6 5.00 Very Low Very Low Very Low
Infliximab 6 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
methotrexate 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 96 61.56 Quite High
Disease 27 50.00 Quite Low
Pain 3 46.08 Quite Low
INFLAMMATION 9 5.00 Very Low Very Low Very Low
Arthritis 6 5.00 Very Low Very Low Very Low
Nasopharyngitis 6 5.00 Very Low Very Low Very Low
Necrosis 6 5.00 Very Low Very Low Very Low
Mycobacterial Infection 6 5.00 Very Low Very Low Very Low
Hepatitis 6 5.00 Very Low Very Low Very Low
Erythema 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Fig Regulation (dependent) of Positive_regulation (increases) of ACR20 associated with adalimumab
1) Confidence 0.02 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Fig Regulation (dependent) of Positive_regulation (increases) of ACR50 associated with adalimumab
2) Confidence 0.02 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Fig Regulation (dependent) of Positive_regulation (increases) of ACR70 associated with adalimumab
3) Confidence 0.02 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox